0001493152-24-020660.txt : 20240520 0001493152-24-020660.hdr.sgml : 20240520 20240520160014 ACCESSION NUMBER: 0001493152-24-020660 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240514 FILED AS OF DATE: 20240520 DATE AS OF CHANGE: 20240520 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lustig Marc CENTRAL INDEX KEY: 0001940908 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40101 FILM NUMBER: 24964258 MAIL ADDRESS: STREET 1: 4177 ROCKRIDGE ROAD CITY: WEST VANCOUVER STATE: A1 ZIP: V7W 1A3 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BriaCell Therapeutics Corp. CENTRAL INDEX KEY: 0001610820 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0731 BUSINESS ADDRESS: STREET 1: 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR CITY: WEST VANCOUVER STATE: A1 ZIP: V7T 2X1 BUSINESS PHONE: (604) 921-1810 MAIL ADDRESS: STREET 1: 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR CITY: WEST VANCOUVER STATE: A1 ZIP: V7T 2X1 FORMER COMPANY: FORMER CONFORMED NAME: Ansell Capital Corp. DATE OF NAME CHANGE: 20140613 4 1 ownership.xml X0508 4 2024-05-14 0 0001610820 BriaCell Therapeutics Corp. BCTX 0001940908 Lustig Marc C/O BRIACELL THERAPEUTICS CORP. 235 15TH STREET,SUITE 300 WEST VANCOUVER A1 V7T 2X1 BRITISH COLUMBIA, CANADA 1 0 1 0 0 Common Shares 2024-05-14 4 P 0 902935 2.215 A 2542935 I By L5 Capital Inc. Common Stock Warrants 2.11 2024-05-14 4 P 0 902935 A Common Stock 902935 902935 I By L5 Capital Inc. The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer. /s/ Marc Lustig 2024-05-20